This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Percentage of Replacement and Smoking Cessation

Lowell C. Dale, MD; Richard D. Hurt, MD; Kenneth P. Offord, MS; George M. Lawson, PhD; Ivana T. Croghan, PhD; Darrell R. Schroeder, MS

JAMA. 1995;274(17):1353-1358.

Abstract
Objective.
—To assess the level of nicotine replacement, evidence of nicotine toxicity, and withdrawal symptom relief with placebo and 11-, 22-, and 44-mg/d doses of transdermal nicotine. A secondary objective was to assess short- and long-term smoking cessation rates.

Design.
—Randomized, double-blind, placebo-controlled inpatient/outpatient trial.

Subjects.
—Seventy-one cigarette smokers stratified according to light (n=23), moderate (n=24), and heavy (n=24) smoking rates.

Interventions.
—After baseline measures were obtained, subjects were randomly assigned to placebo or an 11-, 22-, or 44-mg/d dose of transdermal nicotine and admitted to a special hospital unit for intensive inpatient treatment of nicotine dependence. During the 6-day inpatient stay, daily nicotine and cotinine levels were determined from trough and peak blood samples. Outpatient patch therapy continued for 7 weeks following the hospital stay, and those initially assigned to placebo were randomly assigned to 11 or 22 mg/d. At week 4, the dosage of those initially assigned to 44 mg/d was reduced to 22 mg/d.

Main Outcome Measures.
—Percentage of replacement of cotinine was calculated by dividing the steady-state levels attained during patch therapy by the corresponding baseline levels. Abstinence from smoking was verified by expired air carbon monoxide. Withdrawal symptoms and nicotine toxicity were assessed daily through questionnaires during the inpatient stay. Follow-up visits were at 3,6,9, and 12 months.

Results.
—There was a statistically significant relationship between baseline smoking rate and baseline trough and peak blood cotinine levels (r_s=0.39, r_s=0.45; P<.001 in both instances). A dose-response relationship was observed with higher patch doses, which produced a higher percentage of cotinine replacement and better withdrawal symptom relief. Only one subject (a light smoker assigned to the 44-mg dose) developed signs of nicotine toxicity. There was a positive association between the week 2 patch dose and the biochemically confirmed abstinence at the end of patch therapy (P=.007) but not for subsequent follow-up times. A higher percentage of cotinine replacement was associated with the higher 8-week smoking abstinence rate (P=.03), an association not found at long-term follow-up.

Conclusion.
—A 44-mg/d dose of nicotine patch therapy appears to be safe for use in heavy smokers. Cigarette smoking rates can be used to estimate the initial nicotine patch dose. Monitoring blood cotinine levels at baseline and steady state can be used for assessing the adequacy of nicotine replacement. Withdrawal symptom relief can be improved with more complete nicotine replacement. Achieving a greater percentage of nicotine replacement may increase the efficacy of nicotine patch therapy.

(JAMA. 1995;274:1353-1358)

Author Affiliations
From the Division of Community Internal Medicine and the Nicotine Research Center (Drs Dale and Hurt), the Section of Biostatistics (Messrs Offord and Schroeder), the Department of Laboratory Medicine and Pathology (Dr Lawson), and the Nicotine Research Center (Dr Croghan), Mayo Clinic, Mayo Foundation, Rochester, Minn.

Footnotes
Drs Hurt and Croghan and Mr Offord have worked on clinical research studies funded in part by Lederle Laboratories, Elan Pharmaceutical Research Corporation, Burroughs-Wellcome, and Kabi. Dr Hurt has received honoraria for educational activities from CibaGeigy Corporation, Marion Merrell Dow, Inc, and McNeil Pharmaceuticals. Mr Offord has received honoraria for educational activities from Elan Pharmaceutical Research Corporation.

Reprint requests to Mayo Clinic, 200 First St SW, Rochester, MN 55905 (Dr Dale).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Randomized Placebo-Controlled Clinical Trial of 5 Smoking Cessation Pharmacotherapies
Piper et al.
Arch Gen Psychiatry 2009;66:1253-1262.
ABSTRACT | FULL TEXT  

Treating Tobacco Dependence in a Medical Setting
Hurt et al.
CA Cancer J Clin 2009;59:314-326.
ABSTRACT | FULL TEXT  

Smoking cessation pharmacotherapy
Frishman
Ther Adv Cardiovasc Dis 2009;3:287-308.
ABSTRACT  

A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics
Hays et al.
Nicotine Tob Res 2009;11:859-867.
ABSTRACT | FULL TEXT  

Meta-analysis of studies investigating one-year effectiveness of transdermal nicotine patches for smoking cessation
Myung et al.
Am J Health Syst Pharm 2007;64:2471-2476.
ABSTRACT | FULL TEXT  

Reduction in cortisol after smoking cessation among users of nicotine patches.
Ussher et al.
Psychosom. Med. 2006;68:299-306.
ABSTRACT | FULL TEXT  

Investigating the Receptor-independent Neuroprotective Mechanisms of Nicotine in Mitochondria
Xie et al.
J. Biol. Chem. 2005;280:32405-32412.
ABSTRACT | FULL TEXT  

Pharmacotherapy and Pharmacogenetics of Nicotine Dependence
Berrettini and Lerman
Am. J. Psychiatry 2005;162:1441-1451.
ABSTRACT | FULL TEXT  

Treating Tobacco Dependence: State of the Science and New Directions
Lerman et al.
JCO 2005;23:311-323.
ABSTRACT | FULL TEXT  

Individual Differences in Nicotine Intake per Cigarette
Patterson et al.
Cancer Epidemiol. Biomarkers Prev. 2003;12:468-471.
ABSTRACT | FULL TEXT  

Tobacco Dependence: Why Should an Oncologist Care?
Garces and Hays
JCO 2003;21:1884-1886.
FULL TEXT  

Nicotine Patch Therapy Based on Smoking Rate Followed by Bupropion for Prevention of Relapse to Smoking
Hurt et al.
JCO 2003;21:914-920.
ABSTRACT | FULL TEXT  

Using Nicotine Replacement Therapy in Treating Nicotine Addiction in Adolescents
Maharaj et al.
The Journal of School Nursing 2001;17:278-282.
ABSTRACT | FULL TEXT  

Delirium from nicotine withdrawal in neuro-ICU patients
Mayer et al.
Neurology 2001;57:551-553.
ABSTRACT | FULL TEXT  

Interventions for smoking cessation in hospitalised patients: a systematic review
Munafo et al.
Thorax 2001;56:656-663.
ABSTRACT | FULL TEXT  

New Developments in Smoking Cessation
Prochazka
Chest 2000;117 :169S-175S.
ABSTRACT | FULL TEXT  

Nicotine Patch Therapy in 101 Adolescent Smokers: Efficacy, Withdrawal Symptom Relief, and Carbon Monoxide and Plasma Cotinine Levels
Hurt et al.
Arch Pediatr Adolesc Med 2000;154:31-37.
ABSTRACT | FULL TEXT  

Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up • Commentary: Progress on nicotine replacement therapy for smokers
Blondal et al.
BMJ 1999;318:285-289.
ABSTRACT | FULL TEXT  

A New Gas Chromatography–Mass Spectrometry Method for Simultaneous Determination of Total and Free trans-3'-Hydroxycotinine and Cotinine in the Urine of Subjects Receiving Transdermal Nicotine
Ji et al.
Clin. Chem. 1999;45:85-91.
ABSTRACT | FULL TEXT  

Suppression of Nicotine Intake During Ad Libitum Cigarette Smoking by High-Dose Transdermal Nicotine
Benowitz et al.
J. Pharmacol. Exp. Ther. 1998;287:958-962.
ABSTRACT | FULL TEXT  

Do Heavy Smokers Need a Higher Replacement Dose of Nicotine to Quit?
Westman and Rose
JAMA 1996;275:1882-1882.
ABSTRACT  

Are High-Dose Nicotine Patches Better?
JWatch Psychiatry 1996;1996:19-19.
FULL TEXT  

HIGH-DOSE NICOTINE PATCHES: BETTER THAN STANDARD- DOSE?
JWatch General 1995;1995:4-4.
FULL TEXT  

Treatment of Nicotine Dependence Is More Better?
Hughes
JAMA 1995;274:1390-1391.
ABSTRACT